Trial Outcomes & Findings for A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR] (NCT NCT01846416)

NCT ID: NCT01846416

Last Updated: 2019-01-08

Results Overview

Objective response was defined as a complete response (CR) or partial response (PR), as determined by investigator according to modified RECIST criteria. Modified RECIST was derived from RECIST v1.1 conventions and immune related response criteria. CR was defined as disappearance of all tumor lesions (target lesion \[TL\] and non-target lesion \[non-TL\]) and no new measurable or unmeasurable lesions, all lymph node short axes must be less than 10 millimeters (mm), and PR was defined as at least 30 percent (%) decrease in sum of diameter of TLs and all new measurable lesions since baseline in absence of CR, and both confirmed by consecutive assessment greater than or equal to 4 weeks from date first documented. Participants not meeting these criteria, including participants without at least one post-baseline response assessment were considered as non-responders.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 138 participants
• Primary outcome timeframe: Baseline, and Day 1 of Cycle 1 (21-day cycle), then every 6 weeks for the first 12 months and then every 9 weeks thereafter until disease progression (up to 20 months)
• Results posted on: 2019-01-08

Participant Flow

Overall 201 participants were screened for clinical eligibility, out of which 63 participants were screen failures, and hence 138 participants were enrolled, and 137 participants received treatment.

Participant milestones

Measure	Atezolizumab (MPDL3280) : 1L Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280): 2L+ Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280): 2L+ Brain Metastases Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Treatment Phase STARTED	31	93	13
Treatment Phase COMPLETED	0	0	0
Treatment Phase NOT COMPLETED	31	93	13
Survival Follow-up STARTED	28	80	12
Survival Follow-up COMPLETED	0	0	0
Survival Follow-up NOT COMPLETED	28	80	12

Reasons for withdrawal

Measure	Atezolizumab (MPDL3280) : 1L Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280): 2L+ Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280): 2L+ Brain Metastases Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Treatment Phase Death	2	9	1
Treatment Phase Withdrawal by Subject	2	4	2
Treatment Phase Other	1	5	1
Treatment Phase Physician Decision	1	2	0
Treatment Phase Adverse Event	3	4	0
Treatment Phase Non-compliance	0	2	0
Treatment Phase Study Terminated by Sponsor	1	4	0
Treatment Phase Progressive Disease	21	63	9
Survival Follow-up Death	21	62	9
Survival Follow-up Lost to Follow-up	0	2	2
Survival Follow-up Withdrawal by Subject	2	7	0
Survival Follow-up Study Terminated by Sponsor	2	8	0
Survival Follow-up Other	3	1	1

Baseline Characteristics

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Baseline characteristics by cohort

Measure	Atezolizumab (MPDL3280) : 1L Participants n=31 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants n=93 Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants n=13 Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Total n=137 Participants Total of all reporting groups
Age, Continuous	68 years STANDARD_DEVIATION 10.8 • n=5 Participants	65.2 years STANDARD_DEVIATION 9.3 • n=7 Participants	63.8 years STANDARD_DEVIATION 7.7 • n=5 Participants	65.7 years STANDARD_DEVIATION 9.6 • n=4 Participants
Sex: Female, Male Female	17 Participants n=5 Participants	34 Participants n=7 Participants	7 Participants n=5 Participants	58 Participants n=4 Participants
Sex: Female, Male Male	14 Participants n=5 Participants	59 Participants n=7 Participants	6 Participants n=5 Participants	79 Participants n=4 Participants

PRIMARY outcome

Timeframe: Baseline, and Day 1 of Cycle 1 (21-day cycle), then every 6 weeks for the first 12 months and then every 9 weeks thereafter until disease progression (up to 20 months)

Population: Efficacy-evaluable population; all treated participants who received at least 1 dose of atezolizumab during study.

Objective response was defined as a complete response (CR) or partial response (PR), as determined by investigator according to modified RECIST criteria. Modified RECIST was derived from RECIST v1.1 conventions and immune related response criteria. CR was defined as disappearance of all tumor lesions (target lesion [TL] and non-target lesion [non-TL]) and no new measurable or unmeasurable lesions, all lymph node short axes must be less than 10 millimeters (mm), and PR was defined as at least 30 percent (%) decrease in sum of diameter of TLs and all new measurable lesions since baseline in absence of CR, and both confirmed by consecutive assessment greater than or equal to 4 weeks from date first documented. Participants not meeting these criteria, including participants without at least one post-baseline response assessment were considered as non-responders.

Outcome measures

Measure	Atezolizumab (MPDL3280) : 1L Participants n=31 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants n=93 Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants n=13 Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Percentage of Participants With Objective Response According to Modified Response Evaluation Criteria in Solid Tumors (RECIST)	32 percentage of participants Interval 17.0 to 51.0	21 percentage of participants Interval 13.0 to 30.0	23 percentage of participants Interval 5.0 to 54.0

SECONDARY outcome

Timeframe: Baseline, and Day 1 of Cycle 1 (21-day cycle), then every 6 weeks for the first 12 months and then every 9 weeks thereafter until disease progression (up to 20 months)

Population: Efficacy-evaluable population.

Objective response was defined as a CR or PR, as determined by the investigator according to RECIST v1.1. For TLs, CR was defined as disappearance of all TLs. Any pathological lymph nodes, whether target or non-target, must had reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameter of TLs, taking as reference the baseline sum of diameters, in absence of CR. For non-TLs, CR was defined as disappearance of all non-TLs and if applicable, normalization of tumor marker level. Participants not meeting these criteria, including participants without at least 1 post-baseline response assessment were considered as non-responders.

Outcome measures

Measure	Atezolizumab (MPDL3280) : 1L Participants n=31 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants n=93 Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants n=13 Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Percentage of Participants With Objective Response According to RECIST Version 1.1 (v1.1)	29 percentage of participants Interval 14.0 to 48.0	19 percentage of participants Interval 11.0 to 28.0	23 percentage of participants Interval 5.0 to 54.0

SECONDARY outcome

Timeframe: Baseline, and Day 1 of Cycle 1 (21-day cycle), then every 6 weeks for the first 12 months and then every 9 weeks thereafter until disease progression (up to 20 months)

Population: Efficacy-evaluable population with a confirmed objective response.

Duration of objective response was defined as time from initial occurrence of documented CR or PR until documented disease progression (using RECIST v1.1 as determined by investigator) or death, whichever occurred first. For TLs, CR was defined as disappearance of all TLs. Any pathological lymph nodes, whether target or non-target, must had reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in sum of diameter of TLs, taking as reference baseline sum of diameters, in absence of CR. Progressive disease was at least a 20% increase in sum of diameters of TLs, taking as reference smallest sum on study (nadir). For non-TLs, CR was defined as disappearance of all non-TLs and if applicable, normalization of tumor marker level. Progressive disease was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants were censored at the date of last tumor assessment.

Outcome measures

Measure	Atezolizumab (MPDL3280) : 1L Participants n=9 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants n=17 Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants n=3 Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Duration of Objective Response According to RECIST v1.1	9.2 months Interval 2.3 to 30.4	17.0 months Interval 2.8 to 44.2	NA months Interval 2.8 to 9.9 Median DOR was not reached.

SECONDARY outcome

Timeframe: Month 6

Population: Efficacy-evaluable population with a confirmed objective response.

Duration of objective response at 6 months was defined as time from initial occurrence of documented CR or PR until Month 6. For TLs, CR was defined as disappearance of all TLs. Any pathological lymph nodes, whether target or non-target, must have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in sum of diameter of TLs, taking as reference baseline sum of diameters, in absence of CR. For non-TLs, CR was defined as disappearance of all non-TLs and if applicable, normalization of tumor marker level. Participants were censored at the date of last tumor assessment.

Outcome measures

Measure	Atezolizumab (MPDL3280) : 1L Participants n=8 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants n=15 Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants n=3 Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Percentage of Participants With 6-Month Duration of Objective Response	75.0 percentage of participants	91.7 percentage of participants	66.7 percentage of participants

SECONDARY outcome

Timeframe: Baseline to the first occurrence of progression or death, whichever occurs earlier (up to 20 months)

Population: Efficacy-evaluable population.

For TLs, progressive disease was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest sum on study (nadir). For non-TLs, progressive disease was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs.

Outcome measures

Measure	Atezolizumab (MPDL3280) : 1L Participants n=31 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants n=93 Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants n=13 Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Percentage of Participants With Disease Progression or Death According to RECIST v1.1	67.7 percentage of participants	74.2 percentage of participants	84.6 percentage of participants

SECONDARY outcome

Timeframe: Baseline to the first occurrence of progression or death, whichever occurs earlier (up to 20 months)

Population: Efficacy-evaluable population.

PFS was defined as time from randomization to first occurrence of documented disease progression (based on RECIST v1.1 criteria) or death due to any cause within 30 days of the last treatment, whichever occurs earlier as determined by investigator. For TLs, progressive disease was defined as at least a 20% increase in the sum of diameter of TLs, taking as reference the smallest sum on study (nadir). For non-TLs, progressive disease was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. In event of no disease progression or documented death, PFS was censored at date of last evaluable tumor assessment. Participants with no post-baseline tumor assessments were censored at the time of first dose plus 1 day.

Outcome measures

Measure	Atezolizumab (MPDL3280) : 1L Participants n=31 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants n=93 Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants n=13 Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Progression-Free Survival (PFS) According to RECIST v1.1	4.5 months Interval 0.9 to 37.9	2.7 months Interval 0.0 to 45.5	2.5 months Interval 1.0 to 11.3

SECONDARY outcome

Timeframe: Months 6, 12 and 30

Population: Efficacy-evaluable population.

Percentage of participants who were progression free at Month 6 and 12 (based on RECIST v1.1) was reported. For TLs, progressive disease was defined as at least a 20% increase in the sum of diameter of TLs, taking as reference the smallest sum on study (nadir). For non-TLs, progressive disease was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs.

Outcome measures

Measure	Atezolizumab (MPDL3280) : 1L Participants n=31 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants n=93 Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants n=13 Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 Month 6	33.50 percentage of participants	32.29 percentage of participants	15.38 percentage of participants
Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 Month 12	20 percentage of participants	23 percentage of participants	NA percentage of participants Not estimable
Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 Month 30	13 percentage of participants	10 percentage of participants	NA percentage of participants Not estimable

SECONDARY outcome

Timeframe: Baseline to the first occurrence of progression or death, whichever occurs earlier (up to 20 months)

Population: Efficacy-evaluable population.

For TLs, progressive disease was defined as at least a 20% increase in the sum of diameters of TLs and new measurable lesions, taking as reference the smallest sum recorded since treatment started.

Outcome measures

Measure	Atezolizumab (MPDL3280) : 1L Participants n=31 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants n=93 Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants n=13 Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Percentage of Participants With Disease Progression or Death According to Modified RECIST	58.1 percentage of participants	66.7 percentage of participants	69.2 percentage of participants

SECONDARY outcome

Timeframe: Baseline to the first occurrence of progression or death, whichever occurs earlier (up to 20 months)

Population: Efficacy-evaluable population.

PFS according to modified RECIST was defined as time from first dose of atezolizumab to first occurrence of documented disease progression or death due to any cause, as determined by investigator for participants who discontinued at first documented radiographic progression. For participants who continued beyond first documented progression and had follow-up tumor assessment or death, PFS was defined as time from first dose of atezolizumab to subsequent radiographic progression or death. For TLs, progressive disease was defined as at least a 20% increase in the sum of diameters of TLs and new measurable lesions, taking as reference the smallest sum recorded since treatment started. In event of no disease progression or documented death, PFS was censored at date of last evaluable tumor assessment.

Outcome measures

Measure	Atezolizumab (MPDL3280) : 1L Participants n=31 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants n=93 Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants n=13 Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
PFS According to Modified RECIST	5.5 months Interval 0.9 to 37.9	3.7 months Interval 0.0 to 45.5	4.3 months Interval 1.1 to 16.2

SECONDARY outcome

Timeframe: Months 6, 12 and 30

Population: Efficacy-evaluable population.

Percentage of participants who were progression free at Months 6 and 12 (according to modified RECIST). For TLs, progressive disease was defined as at least a 20% increase in the sum of diameters of TLs and new measurable lesions, taking as reference the smallest sum recorded since treatment started.

Outcome measures

Measure	Atezolizumab (MPDL3280) : 1L Participants n=31 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants n=93 Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants n=13 Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST Month 6	43.12 percentage of participants	39.10 percentage of participants	44.87 percentage of participants
Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST Month 12	31 percentage of participants	29 percentage of participants	24 percentage of participants
Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST Month 30	12 percentage of participants	10 percentage of participants	NA percentage of participants Not estimable

SECONDARY outcome

Timeframe: Baseline till death or up to 20 months, whichever occurred first

Population: Efficacy-evaluable population.

Participants were followed for survival throughout the study.

Outcome measures

Measure	Atezolizumab (MPDL3280) : 1L Participants n=31 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants n=93 Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants n=13 Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Percentage of Participants With Death	74.2 percentage of participants	76.3 percentage of participants	76.9 percentage of participants

SECONDARY outcome

Timeframe: Baseline till death or up to 20 months, whichever occurred first

Population: Efficacy-evaluable population.

OS was defined as the time from first dose of the study drug to the time of death from any cause of the study. Participants who were still alive at the time of analysis were censored at the time of their last study assessment (for active participants) or at the last date known alive (for participants in follow-up). If no post-baseline data were available, OS was censored at the date of first treatment plus 1 day.

Outcome measures

Measure	Atezolizumab (MPDL3280) : 1L Participants n=31 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants n=93 Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants n=13 Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Overall Survival (OS)	14.4 months Interval 12.8 to 22.1	9.3 months Interval 5.8 to 17.6	6.8 months Interval 3.2 to 19.5

SECONDARY outcome

Timeframe: Pre-dose (0 hour) and 30 minutes after infusion on Day 1 of Cycle 1

Population: Pharmacokinetic- evaluable population: All treated participants with pharmacokinetic data at specified time points. Here, Number of participants analyzed = number of participants with available data for this outcome. Per planned analysis, pharmacokinetic data were not analyzed separately for each cohort.

Outcome measures

Measure	Atezolizumab (MPDL3280) : 1L Participants n=135 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Maximum Plasma Concentration (Cmax) for Atezolizumab	405 micrograms per milliliter (mcg/mL) Geometric Coefficient of Variation 31.7	—	—

SECONDARY outcome

Timeframe: Pre-dose (0 hour) on Day 1 of Cycles 2, 3, 4, 8, and 16

Population: Pharmacokinetic- evaluable population. Here, Number of participants analyzed = number of participants with available data for this outcome, and n= number of participants with available data at the specified time point. Per planned analysis, pharmacokinetic data were not analyzed separately for each cohort.

Outcome measures

Measure	Atezolizumab (MPDL3280) : 1L Participants n=125 Participants Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280) : 2L+ Participants Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280) : 2L+ Brain Metastases Participants Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Minimum Plasma Concentration (Cmin) for Atezolizumab Pre-dose Cycle 2 (Day 1) (n= 125)	68.8 mcg/mL Geometric Coefficient of Variation 55.3	—	—
Minimum Plasma Concentration (Cmin) for Atezolizumab Pre-dose Cycle 3 (Day 1) (n= 100)	90.6 mcg/mL Geometric Coefficient of Variation 136.6	—	—
Minimum Plasma Concentration (Cmin) for Atezolizumab Pre-dose Cycle 4 (Day 1) (n= 92)	123 mcg/mL Geometric Coefficient of Variation 136.9	—	—
Minimum Plasma Concentration (Cmin) for Atezolizumab Pre-dose Cycle 8 (Day 1) (n= 51)	206 mcg/mL Geometric Coefficient of Variation 45.9	—	—
Minimum Plasma Concentration (Cmin) for Atezolizumab Pre-dose Cycle 16 (Day 1) (n= 1)	135 mcg/mL Geometric Coefficient of Variation NA Geometric co-efficient of variation was not calculated as only 1 participant was analyzed at the specified time point.	—	—

Adverse Events

Atezolizumab (MPDL3280A) : 1L Participants

Serious events: 17 serious events

Other events: 31 other events

Deaths: 0 deaths

Atezolizumab (MPDL3280A) : 2L+ Participants

Serious events: 46 serious events

Other events: 88 other events

Deaths: 0 deaths

Atezolizumab (MPDL3280A) : 2L+ Brain Metastases Participants

Serious events: 6 serious events

Other events: 13 other events

Deaths: 0 deaths

Serious adverse events

Measure	Atezolizumab (MPDL3280A) : 1L Participants n=31 participants at risk Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280A) : 2L+ Participants n=93 participants at risk Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280A) : 2L+ Brain Metastases Participants n=13 participants at risk Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
Respiratory, thoracic and mediastinal disorders Dyspnoea	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	6.5% 6/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Haemoptysis	9.7% 3/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Pleural effusion	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Pulmonary haemorrhage	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Bronchial obstruction	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Bronchostenosis	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Pulmonary hypertension	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Respiratory disorder	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Pneumonia	9.7% 3/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	8.6% 8/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Lower respiratory tract infection	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Upper respiratory tract infection	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Abscess neck	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Bronchitis	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Groin abscess	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Herpes zoster disseminated	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Influenza	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Sepsis	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Sinusitis	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Cardiac disorders Cardiac tamponade	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Cardiac disorders Pericardial effusion	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Cardiac disorders Atrial flutter	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Cardiac disorders Cardiac arrest	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Cardiac disorders Coronary artery disease	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Cardiac disorders Myocardial infarction	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Cardiac disorders Pericarditis constrictive	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders Back pain	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	3.2% 3/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders Muscular weakness	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Diarrhoea	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Abdominal pain	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Abdominal wall haematoma	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Constipation	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Lower gastrointestinal haemorrhage	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Nausea	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Vomiting	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
General disorders Chest pain	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.4% 2/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
General disorders Pain	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
General disorders Pyrexia	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Guillain-Barre Syndrome	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Intracranial venous sinus thrombosis	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Monoparesis	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Nervous system disorder	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Seizure	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Syncope	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Vocal cord paralysis	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Vascular disorders Deep vein thrombosis	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Vascular disorders Embolism	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Vascular disorders Hypertension	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Vascular disorders Jugular vein thrombosis	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Injury, poisoning and procedural complications Fall	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Injury, poisoning and procedural complications Hip fracture	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Injury, poisoning and procedural complications Spinal compression fracture	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Metabolism and nutrition disorders Dehydration	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Metabolism and nutrition disorders Diabetes mellitus	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Blood and lymphatic system disorders Disseminated intravascular coagulation	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Endocrine disorders Hypothyroidism	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Endocrine disorders Thyroiditis acute	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Eye disorders Amaurosis fugax	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Eye disorders Photopsia	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Investigations Alanine aminotransferase increased	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Investigations Aspartate aminotransferase increased	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Psychiatric disorders Confusional state	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Psychiatric disorders Mental status changes	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Renal and urinary disorders Renal failure	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Cardiac disorders CARDIAC FAILURE CONGESTIVE	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Cardiac disorders PALPITATIONS	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders AUTOIMMUNE COLITIS	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders COLITIS	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Hepatobiliary disorders HEPATIC FUNCTION ABNORMAL	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Investigations INFLUENZA B VIRUS TEST POSITIVE	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Metabolism and nutrition disorders HYPERKALAEMIA	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Metabolism and nutrition disorders HYPONATRAEMIA	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders PAIN IN EXTREMITY	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.

Other adverse events

Measure	Atezolizumab (MPDL3280A) : 1L Participants n=31 participants at risk Participants with no prior chemotherapy for advanced NSCLC disease received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.	Atezolizumab (MPDL3280A) : 2L+ Participants n=93 participants at risk Participants who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.	Atezolizumab (MPDL3280A) : 2L+ Brain Metastases Participants n=13 participants at risk Participants with previously treated brain metastases and who had progressed during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, received atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
General disorders Fatigue	51.6% 16/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	40.9% 38/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	38.5% 5/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
General disorders Pyrexia	22.6% 7/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	22.6% 21/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
General disorders Oedema peripheral	9.7% 3/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.1% 14/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.4% 2/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
General disorders Chest pain	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	9.7% 9/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
General disorders Pain	9.7% 3/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.4% 2/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
General disorders Asthenia	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	9.7% 9/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
General disorders Chills	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	5.4% 5/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
General disorders Influenza like illness	9.7% 3/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	4.3% 4/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
General disorders Malaise	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	6.5% 6/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
General disorders Gait disturbance	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
General disorders General physical health deterioration	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Nausea	35.5% 11/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	29.0% 27/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	30.8% 4/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Constipation	25.8% 8/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	17.2% 16/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	46.2% 6/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Diarrhoea	25.8% 8/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	18.3% 17/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	30.8% 4/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Vomiting	12.9% 4/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.1% 14/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	23.1% 3/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Dysphagia	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	8.6% 8/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Gastrooesophageal reflux disease	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.5% 7/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Abdominal pain	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.5% 7/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Dyspepsia	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	3.2% 3/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Abdominal pain upper	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	5.4% 5/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders Mouth swelling	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Cough	16.1% 5/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	35.5% 33/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	23.1% 3/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Dyspnoea	25.8% 8/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	32.3% 30/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	23.1% 3/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Productive cough	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	14.0% 13/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Wheezing	9.7% 3/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.5% 7/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.4% 2/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Dysphonia	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	6.5% 6/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Haemoptysis	9.7% 3/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	6.5% 6/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Nasal congestion	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	6.5% 6/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Pleural effusion	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	5.4% 5/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.4% 2/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	5.4% 5/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders Arthralgia	19.4% 6/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	19.4% 18/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.4% 2/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders Back pain	12.9% 4/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	20.4% 19/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.4% 2/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders Pain in extremity	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	8.6% 8/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	12.9% 4/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	9.7% 9/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	8.6% 8/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders Myalgia	9.7% 3/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	5.4% 5/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders Neck pain	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	5.4% 5/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	3.2% 3/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	4.3% 4/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Metabolism and nutrition disorders Decreased appetite	19.4% 6/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	23.7% 22/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.4% 2/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Metabolism and nutrition disorders Hypokalaemia	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	12.9% 12/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	30.8% 4/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Metabolism and nutrition disorders Hyponatraemia	9.7% 3/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	12.9% 12/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Metabolism and nutrition disorders Dehydration	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.5% 7/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	8.6% 8/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Metabolism and nutrition disorders Hypercalcaemia	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	6.5% 6/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Metabolism and nutrition disorders Hypoalbuminaemia	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	6.5% 6/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Skin and subcutaneous tissue disorders Pruritus	16.1% 5/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	9.7% 9/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Skin and subcutaneous tissue disorders Dry skin	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	12.9% 12/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Skin and subcutaneous tissue disorders Night sweats	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.5% 7/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Skin and subcutaneous tissue disorders Rash	9.7% 3/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	9.7% 9/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Skin and subcutaneous tissue disorders Decubitus ulcer	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Skin and subcutaneous tissue disorders Acne	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Skin and subcutaneous tissue disorders Dermatitis	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Upper respiratory tract infection	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	18.3% 17/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Pneumonia	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	8.6% 8/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Urinary tract infection	22.6% 7/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	3.2% 3/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.4% 2/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Candida infection	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Cystitis	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Fungal skin infection	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Influenza	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations Respiratory tract infection	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Psychiatric disorders Insomnia	12.9% 4/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	11.8% 11/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Psychiatric disorders Anxiety	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	11.8% 11/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.4% 2/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Psychiatric disorders Depression	9.7% 3/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	9.7% 9/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Psychiatric disorders Confusional state	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	4.3% 4/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Psychiatric disorders Hallucination	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Blood and lymphatic system disorders Anaemia	19.4% 6/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	20.4% 19/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Blood and lymphatic system disorders Neutropenia	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Blood and lymphatic system disorders Thrombocytopenia	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Headache	16.1% 5/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	10.8% 10/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	23.1% 3/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Dizziness	12.9% 4/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	8.6% 8/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Dysgeusia	12.9% 4/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	4.3% 4/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Cognitive disorder	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Hemiparesis	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Memory impairment	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Nystagmus	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders Syncope	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Investigations Weight decreased	19.4% 6/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	9.7% 9/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Investigations Alanine aminotransferase increased	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.4% 2/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Investigations Aspartate aminotransferase increased	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	3.2% 3/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.4% 2/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Investigations LYMPHOCYTE COUNT DECREASED	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	3.2% 3/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Investigations Blood alkaline phosphatase increased	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Investigations Haemoglobin decreased	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Investigations Blood thyroid stimulating hormone increased	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Vascular disorders Hypotension	9.7% 3/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	9.7% 9/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Vascular disorders Hypertension	9.7% 3/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	3.2% 3/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Vascular disorders Hot flush	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Vascular disorders Haematoma	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Cardiac disorders Tachycardia	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	3.2% 3/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Cardiac disorders Atrial fibrillation	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Cardiac disorders Pericardial effusion	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Cardiac disorders Aortic valve thickening	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Eye disorders Diplopia	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Eye disorders Lacrimation increased	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Eye disorders Vision blurred	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Eye disorders Periorbital oedema	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	4.3% 4/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	15.4% 2/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Ear and labyrinth disorders Vertigo	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Ear and labyrinth disorders EXCESSIVE CERUMEN PRODUCTION	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Ear and labyrinth disorders Deafness bilateral	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Ear and labyrinth disorders Ear pain	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Ear and labyrinth disorders Vestibular disorder	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Endocrine disorders Hypothyroidism	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	3.2% 3/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Injury, poisoning and procedural complications FALL	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	6.5% 6/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Injury, poisoning and procedural complications JAW FRACTURE	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Injury, poisoning and procedural complications LACERATION	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Reproductive system and breast disorders Breast swelling	3.2% 1/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Immune system disorders Drug hypersensitivity	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Eye disorders CONJUNCTIVAL HYPERAEMIA	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	1.1% 1/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders ABDOMINAL PAIN LOWER	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	3.2% 3/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Gastrointestinal disorders STOMATITIS	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	3.2% 3/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Infections and infestations SINUSITIS	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	2.2% 2/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Injury, poisoning and procedural complications LIMB INJURY	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	7.7% 1/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders FLANK PAIN	0.00% 0/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	5.4% 5/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Musculoskeletal and connective tissue disorders MUSCULAR WEAKNESS	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	4.3% 4/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Nervous system disorders PARAESTHESIA	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	4.3% 4/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders CHRONIC OBSTRUCTIVE PULMONARY DISEASE	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Respiratory, thoracic and mediastinal disorders OROPHARYNGEAL PAIN	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	5.4% 5/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.
Skin and subcutaneous tissue disorders RASH MACULO-PAPULAR	6.5% 2/31 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	3.2% 3/93 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.	0.00% 0/13 • Baseline until 20 months. All participants who received at least one dose of atezolizumab were included in analysis.

Additional Information

Medical Communications

Hoffmann-La Roche

Phone: 800-821-8590

Email: genentech@druginfo.com

Results disclosure agreements

• Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
• Publication restrictions are in place

Restriction type: OTHER